You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
神威藥業(02877.HK)中期溢利3.31億元 同比上升7.3%
格隆匯 08-30 12:06

神威藥業(02877.HK)公吿,截至2022年6月30日止6個月,營業額為人民幣18.15億元,比去年同期上升16.8%;期內溢利為人民幣3.31億元,比去年同期上升7.3%;每股盈利為人民幣44分,比去年同期上升7.3%;宣派2022年第二次中期股息每股人民幣11分;每股淨現金人民幣5.4元(相等於6.3港元)。

集團繼續以拓展口服制劑為重點發展策略,於2022年首6個月,口服產品整體銷售額同比增長21.7%,其中軟膠囊、顆粒劑和中藥配方顆粒產品銷售額較去年同期分別上升7.6%、8.2%及46.0%。口服產品佔總銷售額從去年同期的59.1%上升至61.6%。與此同時,注射液產品銷售額共錄得9.7%增長。注射液產品佔本集團總銷售額從去年同期的40.9%下降至38.4%,其銷售比重持續減少。

2022年是集團中藥配方顆粒騰飛發展的一年。市場開放的政策已然推動了中藥配方顆粒市場擴容。在市場格局改變際,集團克服了疫情種種影響,搶抓市場機遇,以快速的反應、技術工藝的優勢、過硬的質量和優越的客户服務,驅使集團中藥配方顆粒呈快速發展,於期內銷售額大幅上升46.0%,佔集團總銷售額亦從去年同期的20.7%上升至25.9%。而根據內部的未經審核數據,集團中藥配方顆粒於2022年7月單月錄得含税銷售額超越了一億元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account